arrow
A

Alan C. Swann

menninger department of psychiatry and behavioral sciences
H指数:80
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A randomized, controlled experimental medicine study of the novel Kv7 channel opener azetukalner in individuals with major depressive disorder and anhedonia

一项关于新型Kv7通道开放剂azetukalner在伴有快感缺乏的重度抑郁症患者中的随机对照实验药物研究

2026-10-070
OA
Mitigating Post-Traumatic Stress Disorder Risk Through Gender-Sensitive Trauma-Informed Care in the Emergency Department-A Narrative Review

通过在急诊科实施性别敏感的创伤知情护理来降低创伤后应激障碍风险——一篇叙事性综述

2025-11-010
PRE
Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial

Chowdhury, A.; Boukezzi, S.; Costi, S.; Hameed, S.; Jacob, Y.; Salas, R.; Iosifescu, D.V.; Han, M.-H.; Swann, A.; Mathew, S.J.; 等. KCNQ (Kv7) 通道开放剂Ezogabine对纹状体脑奖赏区域静息态功能连接、抑郁及快感缺乏的影响:一项随机对照试验的结果. Biol. Psychiatry 2025. [Google Scholar] [CrossRef] [PubMed]

2025-03-040
PRE
Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder
2024-03-150
OA
The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management

旨在个性化管理的成年双相情感障碍患者的临床特征

2022-09-0871
OAAI
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results Froma Randomized Controlled Trial
2021-05-0144
OA